BenevolentAI Investor Presentation Deck
BenevolentAl is revolutionising drug discovery
Our mechanism-based approach empowers scientists to make better decisions in the earliest stages of drug
discovery, aiming to avoid late-stage failure and discover novel targets with a higher probability of clinical success.
Knowledge Discovery
Integrated Knowledge platform
built to ingest, represent, and
surface insights from large volumes
of diverse data types
Predictive
algorithms
Precision Medicine
Biological
question
<<<<<<<
Experimental
validation
Target Triage
Target identification
Suite of Al-driven tools and precision
medicine workflows allow scientists to
explore underlying mechanisms and
discover novel targets with high confidence
HIGHER CONFIDENCE TARGET
IDENTIFICATION
Our Al platform supports scientists in
exploring and assessing insights
generated from our knowledge
foundations, and is built on feedback
from our in-house labs to continuously
improve the quality of our target
predictions.
EMPOWERING SCIENTISTS TO
✔ Decipher complex disease biology
✓ Discover novel targets
✓ Run in-silico experiments in real time
✔ Accelerate the development of
drug candidates
✔ Make high confidence decisions
using a rigorous candidate selection
processView entire presentation